California-based startup Mission Bio has raised a brand-new$70 million Series C financing round, led by Novo Growth and consisting of participation from Soleus Capital and existing investors Mayfield, Cota and Agilent. Mission Bio will use the funding to scale its Tapestri Platform, which uses the business’s work in single-cell multi-omics technology to assist enhance scientific trials for targeted, precision cancer treatments.
Objective Bio’s single-cell multi-omics platform is unique in the restorative market. What it permits is the capability to no in on a single cell, observing both genotype (fully hereditary) and phenotype (observable characteristics influenced by genetics and other elements) effect resulting from use of various treatments throughout clinical trials. Objective’s Tapestri can identify both DNA and protein changes within the same single cell, which is type in identifying efficiency of targeted treatments due to the fact that it can assist dismiss the impact of other elements not under control when analyzing in bulk (i.e. throughout groups of cells).
Founded in 2012 as a spin-out of research work conducted at UCSF, Mission Bio has raised a total of $120 million to date. The company’s tech has been utilized by a number of big pharmaceutical and therapeutic business, including Agios, LabCorp and Onconova Rehabs, as well as at cancer proving ground including UCSF, Stanford and the Memorial Sloan Kettering Cancer Center. In addition to assisting with the optimization of
scientific trials for treatments of blood cancers and tumors, Mission’s tech can be used to validate genome editing– a large prospective market that might see a great deal of growth over the next couple of years with the increase of CRISPR-based healing applications. Article curated by RJ Shara from Source. RJ Shara is a Bay Area Radio Host (Radio Jockey) who talks about the startup ecosystem – entrepreneurs, investments, policies and more on her show The Silicon Dreams. The show streams on Radio Zindagi 1170AM on Mondays from 3.30 PM to 4 PM.